This week, we now have 4 interviews: Franjo Hanzl, vp industrial growth Europe at Eversana; Stacy Blain, founder and CEO of Concarlo Therapeutics; Jens Hennecke, vp of enterprise growth at SOTIO Biotech; and Carl Borrebaeck, chairman of the board of administrators of Immunovia and professor on the Division of Immunotechnology on the College of Lund in Sweden.

Concarlo Therapeutics

Concarlo Therapeutics is a U.S.-based preclinical-stage precision-medicine oncology firm. It’s growing a novel remedy for drug-resistant metastatic breast most cancers as a primary indication.

Concarlo’s patented IpY, a novel therapeutic peptide, would be the first to hit two targets, each CDK4/6- pushed cell proliferation and CDK2-driven drug resistance on the identical time, and the primary to focus on p27. 

It’s a particular mobile pathway to kill most cancers cells slightly than simply slowing their proliferation.

The novel strategy depends on the function of p27Kpi, a pure inhibitor, an  “on-off” change that regulates the actions of the main cancer-related proteins, CDK6, CDK4, and CDK2. 


Eversana is a supplier of worldwide providers to the life sciences business. 

Its built-in options are rooted within the affected person expertise and span all phases of the product life cycle to ship long-term, sustainable worth for sufferers, prescribers, channel companions and payers. The corporate serves greater than 500 organizations, together with start-ups and established pharmaceutical corporations, to advance life sciences options.

Labiotech spoke with Franjo Hanzl, vp industrial growth Europe, on the Medicon Valley Alliance annual summit in Copenhagen, Denmark.

Medicon Village

Throughout NLS Days, Labiotech visited Medicon Village, in Lund, Sweden. Whereas there, we had the chance to speak with Carl Borrebaeck. To say he’s concerned in biotech could be an understatement. He’s chairman of the board of administrators of Immunovia and professor on the Division of Immunotechnology on the College of Lund in Sweden, in addition to being director of Create Well being. 

Borrebaeck, former vp of the College of Lund, has been concerned in lots of corporations all through his profession, together with Alligator Bio, SenzaGen and PainDrainer. 

He acquired the AKZONobel Science Award 2009, for contributions to most cancers proteomics and antibody-based remedy, a Analysis! Sweden Award 2012 for his medical analysis of worth for sufferers and well being organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for excellent contributions to biomedical science. He was honored because the Biotech Builder of the Yr in 2017.

SOTIO Biotech

SOTIO Biotech is a scientific stage immuno-oncology firm owned by PPF Group based mostly in Prague, Czechia. The corporate is constructing a pipeline of oncology applications by pursuing promising early-stage candidates by way of strategic licensing, M&A and in-house discovery efforts. 

SOTIO has been lively within the clinic in 2022. The corporate initiated two scientific trials, the primary was a section 2 research for its lead IL-15 superagonist, SOT101. The initiation of the AURELIO-04 trial comes on the heels of constructive section 1/1b knowledge, which confirmed 15 of 19 sufferers with superior/metastatic strong tumors demonstrated scientific profit with SOT101 together with pembrolizumab. 

The corporate additionally plans to enter the CAR-T house with the initiation of its BOXR trial in Q3 2022.  SOTIO is properly funded into 2023 and plans to make use of these funds for posting extra knowledge throughout its already promising applications.

We spoke with SOTIO Biotech at BIO-Europe.

Source link